Get the Stockscreener App
3.995
4.20%
-0.175
Revance Therapeutics Inc stock is traded at $3.995, with a volume of 1.09M.
It is down -4.20% in the last 24 hours and down -24.48% over the past month.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
See More
Previous Close:
$4.17
Open:
$4.18
24h Volume:
1.09M
Relative Volume:
0.31
Market Cap:
$424.44M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
-0.8819
EPS:
-4.53
Net Cash Flow:
$-223.46M
1W Performance:
+15.80%
1M Performance:
-24.48%
6M Performance:
+32.28%
1Y Performance:
-45.05%
1-Day Range:
$3.98
$4.185
1-Week Range:
$3.42
$4.365
52-Week Range:
$2.30
$9.745
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
(615) 724-7755
Address
1222 DEMONBREUN STREET, NASHVILLE, CA
Compare RVNC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RVNC | 3.995 | 424.44M | 234.04M | -323.92M | -223.46M | -4.53 |
| VRTX | 467.20 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 760.66 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.32 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.33 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-22-22 | Initiated | Goldman | Buy |
| Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-15-20 | Reiterated | Needham | Buy |
| Aug-11-20 | Resumed | Mizuho | Buy |
| Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
| Dec-02-19 | Initiated | Goldman | Buy |
| Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Feb-15-19 | Initiated | Wells Fargo | Market Perform |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
| Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Apr-20-18 | Reiterated | Mizuho | Buy |
| Mar-27-18 | Initiated | Needham | Buy |
| Mar-05-18 | Initiated | Goldman | Buy |
| Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-06-17 | Initiated | Guggenheim | Buy |
| Dec-06-17 | Reiterated | Mizuho | Buy |
| Nov-27-17 | Initiated | Barclays | Overweight |
| Nov-17-17 | Initiated | Mizuho | Buy |
| Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
LMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Neurotoxin Market Overall Study Report 2024-2032 | Revance - openPR
Revance, Crown Labs Again Extend Tender Offer Start Deadline - MarketWatch
Revance Therapeutics jumps after Crown Laboratories tender offer extended again - MSN
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders - GlobeNewswire Inc.
Where are the Opportunities in (RVNC) - Stock Traders Daily
Revance Therapeutics (NASDAQ:RVNC) Given Hold Rating at Needham & Company LLC - MarketBeat
Revance Therapeutics' (RVNC) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Revance Therapeutics Reports Q3 Growth Amid Merger Plans - TipRanks
Revance Therapeutics sinks amid `going concern' disclosure - MSN
Revance Therapeutics Q3 2024 Earnings: EPS of -$0.37 Beats Estimate, Revenue of $59.9M Misses Expectations - GuruFocus.com
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Revance Q3 Revenue Up 11% to $59.9M Amid Crown Merger Deal; China Approves DAXXIFY | RVNC Stock News - StockTitan
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in September - MarketBeat
AQR Capital Management LLC Has $517,000 Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Algert Global LLC Sells 127,260 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
M&A Took A Holiday In Q3, With Decreased Volume And Value - Citeline News & Insights
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Revance Therapeutics Inc Stock (RVNC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sjuts Dustin S | President |
Mar 18 '24 |
Sale |
5.04 |
9,211 |
46,446 |
167,550 |
| Moxie Dwight | CLO & GC |
Mar 18 '24 |
Sale |
5.04 |
8,125 |
40,971 |
137,815 |
| Schilke Tobin | CFO |
Mar 18 '24 |
Sale |
5.04 |
9,361 |
47,204 |
192,666 |
| Foley Mark J | CEO |
Mar 06 '24 |
Buy |
6.98 |
30,000 |
209,400 |
1,015,468 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):